A5046962135- Multiple Myeloma Research and Treatments
- CAR-T cell therapy research
- Protein Degradation and Inhibitors
- Immune Cell Function and Interaction
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Synthesis and Biological Evaluation
- Chronic Lymphocytic Leukemia Research
- Acute Myeloid Leukemia Research
- Monoclonal and Polyclonal Antibodies Research
- Peptidase Inhibition and Analysis
- Sport and Mega-Event Impacts
- Quinazolinone synthesis and applications
- Histone Deacetylase Inhibitors Research
- Sarcoma Diagnosis and Treatment
- Ubiquitin and proteasome pathways
- Physical Education and Pedagogy
- Cancer therapeutics and mechanisms
- Social and Educational Sciences
- Cancer Treatment and Pharmacology
- Lymphoma Diagnosis and Treatment
- Hematological disorders and diagnostics
- Cancer Mechanisms and Therapy
- Chronic Myeloid Leukemia Treatments
- Malaria Research and Control
- Immunotherapy and Immune Responses
University of Colorado Denver
2017-2025
University of Colorado Cancer Center
2022-2025
Colorado Blood Cancer Institute
2025
Danish Institute for International Studies
2014-2024
University of Colorado Anschutz Medical Campus
2016-2024
University of Colorado Health
2023-2024
New York Hospital Queens
2013-2016
Presbyterian Hospital
2013-2016
NewYork–Presbyterian Hospital
2013-2016
Cornell University
2013-2016
PURPOSE Idecabtagene vicleucel (ide-cel) and ciltacabtagene autoleucel (cilta-cel), two B-cell maturation antigen–directed chimeric antigen receptor (CAR) T-cell therapies have demonstrated remarkable efficacy in relapsed/refractory multiple myeloma (RRMM). We compare safety, efficacy, survival among patients with RRMM treated standard-of-care (SOC) ide-cel or cilta-cel. METHODS Data were from a retrospective chart review of leukapheresed by December 31, 2022, the intent to receive SOC...
Abstract T cell–engaging antibodies (TCEs) are showing promising efficacy in relapsed/refractory multiple myeloma, even patients that relapsed after B-cell maturation antigen (BCMA)-targeted therapy. Patients with myeloma may have compromised T-cell health unaccounted for by preclinical models. Here, we use Myeloma Drug Sensitivity Testing (My-DST) ex vivo measurement of anti-multiple cytotoxicity the trispecific CD38/CD28xCD3 TCE SAR442257 through activation patients’ own endogenous cells...
Physical activity plays an important role in public health, owing to a range of health-related benefits that it provides. Sports-related injuries are known be barrier continued physical activity. Still, the prevalence on general population level has not yet been explored descriptive epidemiological investigation. The purpose questionnaire-based study, therefore, was describe injury representative sample Danish population.Two samples 10,000 adults (> 15 years) and 6500 children adolescents...
Abstract We compared outcomes among adult matched related donor (MRD) patients undergoing peripheral blood stem cell transplantation and double unit cord (CBT) at our center between 2010 2017. A total of 190 CBT were with 123 MRD patients. Median follow-up was 896 days (range, 169-3350) surviving 1262 249-3327) Comparing all patients, overall survival (OS) comparable (P = .61) graft-versus-host disease (GVHD) relapse-free (GRFS) significantly improved .0056), primarily because decreased...
Monoclonal antibodies targeting CD38 are important for treatment of both newly diagnosed and relapsed multiple myeloma (MM). Daratumumab isatuximab anti-CD38 with the US Food Drugs Administration approval in different combinations. Despite good initial efficacy, patients inevitably develop drug resistance. Whether can be effectively re-treated these subsequent lines therapy is unclear. Thus far, studies have mostly been limited to clinical retrospectives short washout periods. To answer...
<p>HIF1 Signaling Pathway Genes Overexpressed in IGH-MM.</p>
<p>Relapse and disease progression associated with dysregulated apoptosis increasing drug resistance. <b>A,</b> Volcano plot showing the differential gene expression between LCE-multiple myeloma (MM) cells at timepoint 1 (diagnosis) LCE-MM 2 (first relapse, 1,042 genes higher in diagnosis, 281 first indicated by green dots for l<sub>2</sub>FC > 0.25, <i>P</i> < 0.05). Tested linear regression, <i>n</i> = 4,370 relapse....
<p>Top 15 genes higher in LCE-MM vs IGH-MM at diagnosis.</p>
<p>Gene Expression at First Relapse Exhibiting a Dysregulation of Apoptosis.</p>
<p>Immunoglobulin Heavy Chain Genes were the Top Overexpressed in IGH-MM.</p>
<div>Abstract<p>High-risk multiple myeloma is genomically unstable, comprising heterogeneous populations of tumor cells that evolve over time. Light chain escape (LCE) a clinical phenomenon observed when light chains rise separately from M-spike values, which implies divergent evolution. We sought to understand LCE by performing high-depth transcriptomic and phenotypic studies. performed single-cell RNA-sequencing (scRNA-seq) <i>ex vivo</i> drug sensitivity profiling...
<p>Oxidative Phosphorylation Pathway Genes Overexpressed in LCE-MM.</p>
<p>Patient with two multiple myeloma (MM) subpopulations correlating separately to monoclonal protein and free light chain detection through the course of disease. <b>A,</b> UMAP clustering analysis bone marrow biopsy samples from patient #1093 at all three timepoints showed distinct MM cells (LCE-MM IGH-MM), along expected normal cell types. <b>B,</b> Both displayed transcript expression for prototypical markers including high <i>CD138</i>,...
<p>Top 15 genes higher in IGH-MM vs LCE-MM at diagnosis.</p>
<p>Infer Copy Number Variant Analysis for Subclonal Tracking.</p>
<p>Characterization of LAMP5 Effects on MM cell Prognosis, Prognosis and Viability.</p>
<p>Normal Bone Marrow Cell Populations Across Timepoints.</p>
<p>Multiple myeloma (MM) subpopulation gene-set exhibits osteolytic features and is detrimental to OS. <b>A,</b> Through the disease course for patient #1093, spikes in serum calcium occurred during periods of activity with high levels LCE-MM. <b>B,</b> The GEP70 score high-risk MM was significantly higher LCE-MM compared IGH-MM subpopulation. <b>C,</b> Five key genes were even more upregulated IGH-MM. <b>D,</b> In MMRF cohort, 325...
<p>The IGH-MM Gene Signature Was Not Associated with Adverse Prognosis.</p>
<p>Patients from the CoMMpass database with LCE have a poor prognosis. <b>A,</b> Fifteen patients identified showed significantly shorter PFS diagnosis than those without LCE. <b>B,</b> Patients OS <b>C,</b> high <i>LAMP5</i> expression had trend toward compared and low <i>LAMP5</i>. <b>D,</b> nonsignificantly <b>E,</b> time to diffuse lytic lesions <b>F,</b> In particular, all both at...